Skip to main content

Table 6 Adverse events reported in the included studies

From: Omalizumab vs. placebo in the management of chronic idiopathic urticaria: a systematic review

Study ID Sample size Intervention At least 1 adverse event n(%) Adverse event during follow up, n(%) Event allegedly caused drug n(%) Serious adverse event n(%)
1 27 Omalizumab 75-375 mg 22 (81.5) - 6 (22.2) -
22 Placebo 19 (86.4) - 6 (22.7) -
2 23 Omalizumab 75 mg 8 (34.8) 9 (50.0) - -
25 Omalizumab 300 mg 12 (48.0) 12 (52.2) - -
21 Omalizumab 600 mg 10 (47.6) 5 (25.0) - -
21 Placebo 10 (47.6) 7 (35.0) - -
3 82 75 mg omalizumab 45 (59) - 7 (9) 4 (5)
83 150 mg omalizumab 59 (67) - 8 (9) 5 (6)
79 300 mg omalizumab 51 (65) - 7 (9) 6 (8)
79 placebo 48 (61) - 3 (4) 7 (9)
4 252 Omalizumab 300 mg 211 (83.7) - 28 (11.1) 18 (7.1)
84 Placebo 65 (78.3) - 11 (13.3) 5 (6)
5 78 Omalizumab 75 mg 55 (78.6) 36 (51.4) 6 (8.6) 2 (2.9)
80 Omalizumab 150 mg 72 (82.8) 45 (51.7) 9 (10.3) 5 (5.7)
81 Omalizumab 300 mg 57 (70.4) 38 (46.9) 14 (17.3) 2 (2.5)
80 Placebo 53 (66.3) 32 (40.0) 4 (5.0) 5 (6.3)